Comment
doi: 10.1001/jamacardio.2017.2911.
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value
Affiliations
- PMID: 28832860
- DOI: 10.1001/jamacardio.2017.2911
Item in Clipboard
Comment
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value
JAMA Cardiol.
.
No abstract available
Comment on
-
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.JAMA Cardiol. 2017 Oct 1;2(10):1069-1078. doi: 10.1001/jamacardio.2017.2762. JAMA Cardiol. 2017. PMID: 28832867 Free PMC article.
Similar articles
-
Lipid-Lowering Therapy With Monoclonal Antibodies to Proprotein Convertase Subtilisin-Kexin Type 9 - Lessons From Recent Clinical Trials.Circ J. 2017 Sep 25;81(10):1386-1387. doi: 10.1253/circj.CJ-17-0511. Epub 2017 Jun 3. Circ J. 2017. PMID: 28579602 No abstract available.
-
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.Circulation. 2013 Aug 27;128(9):962-9. doi: 10.1161/CIRCULATIONAHA.113.001969. Epub 2013 Jul 24. Circulation. 2013. PMID: 23884353 Clinical Trial.
-
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):19-31. doi: 10.1016/j.pcad.2015.04.004. Epub 2015 May 1. Prog Cardiovasc Dis. 2015. PMID: 25936907 Review.
-
[Gene mutations of proprotein convertase subtilisin/kexin type 9 and low density lipoprotein-cholesterol].Zhonghua Xin Xue Guan Bing Za Zhi. 2017 May 24;45(5):444-446. doi: 10.3760/cma.j.issn.0253-3758.2017.05.018. Zhonghua Xin Xue Guan Bing Za Zhi. 2017. PMID: 28511335 Chinese. No abstract available.
-
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.JAMA Intern Med. 2016 Jan;176(1):107-8. doi: 10.1001/jamainternmed.2015.7248. JAMA Intern Med. 2016. PMID: 26662572 Review. No abstract available.
Cited by
-
Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.JAMA Cardiol. 2019 Jul 1;4(7):691-695. doi: 10.1001/jamacardio.2019.1647. JAMA Cardiol. 2019. PMID: 31166576 Free PMC article. Clinical Trial.
-
Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria.Cardiovasc Drugs Ther. 2019 Apr;33(2):189-199. doi: 10.1007/s10557-019-06864-2. Cardiovasc Drugs Ther. 2019. PMID: 30746585 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
